Denali Therapeutics (DNLI) Equity Average (2018 - 2026)

Denali Therapeutics (DNLI) has 9 years of Equity Average data on file, last reported at $969.9 million in Q1 2026.

• Equity Average for Q1 2026 came in at $969.9 million, down 17.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $969.9 million (down 17.54% YoY), and the FY2025 annual result was $1.1 billion, down 0.76% from the prior year.
• Equity Average held at $969.9 million in Q1 2026 per DNLI's latest filing, from $970.0 million in the prior quarter.
• Over five years, Equity Average peaked at $1.4 billion in Q2 2024 and troughed at $847.9 million in Q3 2022.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2023 and 2025: Equity Average jumped 35.94% in 2023, then retreated 27.81% in 2025.
• A 5-year view of Equity Average shows it stood at $926.9 million in 2022, then increased by 15.94% to $1.1 billion in 2023, then increased by 18.56% to $1.3 billion in 2024, then retreated by 23.87% to $970.0 million in 2025, then slipped by 0.01% to $969.9 million in 2026.
• Business Quant data shows DNLI's Equity Average at $969.9 million in Q1 2026, $970.0 million in Q4 2025, and $976.6 million in Q3 2025.